Cargando…

Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels)

Accumulating evidence (mainly from experimental research) suggests that metformin possesses anticancer properties through the induction of apoptosis and inhibition of the growth and proliferation of cancer cells. However, its effect on the enzymes responsible for histone acetylation status, which pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Szymczak-Pajor, Izabela, Drzewoski, Józef, Świderska, Ewa, Strycharz, Justyna, Gabryanczyk, Anna, Kasznicki, Jacek, Bogdańska, Marta, Śliwińska, Agnieszka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863441/
https://www.ncbi.nlm.nih.gov/pubmed/36678613
http://dx.doi.org/10.3390/ph16010115
_version_ 1784875335261618176
author Szymczak-Pajor, Izabela
Drzewoski, Józef
Świderska, Ewa
Strycharz, Justyna
Gabryanczyk, Anna
Kasznicki, Jacek
Bogdańska, Marta
Śliwińska, Agnieszka
author_facet Szymczak-Pajor, Izabela
Drzewoski, Józef
Świderska, Ewa
Strycharz, Justyna
Gabryanczyk, Anna
Kasznicki, Jacek
Bogdańska, Marta
Śliwińska, Agnieszka
author_sort Szymczak-Pajor, Izabela
collection PubMed
description Accumulating evidence (mainly from experimental research) suggests that metformin possesses anticancer properties through the induction of apoptosis and inhibition of the growth and proliferation of cancer cells. However, its effect on the enzymes responsible for histone acetylation status, which plays a key role in carcinogenesis, remains unclear. Therefore, the aim of our study was to evaluate the impact of metformin on histone acetyltransferases (HATs) (i.e., p300/CBP-associated factor (PCAF), p300, and CBP) and on histone deacetylases (HDACs) (i.e., SIRT-1 in human pancreatic cancer (PC) cell lines, 1.2B4, and PANC-1). The cells were exposed to metformin, an HAT inhibitor (HATi), or a combination of an HATi with metformin for 24, 48, or 72 h. Cell viability was determined using an MTT assay, and the percentage of early apoptotic cells was determined with an Annexin V-Cy3 Apoptosis Detection Assay Kit. Caspase-9 activity was also assessed. SIRT-1, PCAF, p300, and CBP expression were determined at the mRNA and protein levels using RT-PCR and Western blotting methods, respectively. Our results reveal an increase in caspase-9 in response to the metformin, indicating that it induced the apoptotic death of both 1.2B4 and PANC-1 cells. The number of cells in early apoptosis and the activity of caspase-9 decreased when treated with an HATi alone or a combination of an HATi with metformin, as compared to metformin alone. Moreover, metformin, an HATi, and a combination of an HATi with metformin also modified the mRNA expression of SIRT-1, PCAF, CBP, and p300. However, metformin did not change the expression of the studied genes in 1.2B4 cells. The results of the Western blot analysis showed that metformin diminished the protein expression of PCAF in both the 1.2B4 and PANC-1 cells. Hence, it appears possible that PCAF may be involved in the metformin-mediated apoptosis of PC cells.
format Online
Article
Text
id pubmed-9863441
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98634412023-01-22 Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels) Szymczak-Pajor, Izabela Drzewoski, Józef Świderska, Ewa Strycharz, Justyna Gabryanczyk, Anna Kasznicki, Jacek Bogdańska, Marta Śliwińska, Agnieszka Pharmaceuticals (Basel) Article Accumulating evidence (mainly from experimental research) suggests that metformin possesses anticancer properties through the induction of apoptosis and inhibition of the growth and proliferation of cancer cells. However, its effect on the enzymes responsible for histone acetylation status, which plays a key role in carcinogenesis, remains unclear. Therefore, the aim of our study was to evaluate the impact of metformin on histone acetyltransferases (HATs) (i.e., p300/CBP-associated factor (PCAF), p300, and CBP) and on histone deacetylases (HDACs) (i.e., SIRT-1 in human pancreatic cancer (PC) cell lines, 1.2B4, and PANC-1). The cells were exposed to metformin, an HAT inhibitor (HATi), or a combination of an HATi with metformin for 24, 48, or 72 h. Cell viability was determined using an MTT assay, and the percentage of early apoptotic cells was determined with an Annexin V-Cy3 Apoptosis Detection Assay Kit. Caspase-9 activity was also assessed. SIRT-1, PCAF, p300, and CBP expression were determined at the mRNA and protein levels using RT-PCR and Western blotting methods, respectively. Our results reveal an increase in caspase-9 in response to the metformin, indicating that it induced the apoptotic death of both 1.2B4 and PANC-1 cells. The number of cells in early apoptosis and the activity of caspase-9 decreased when treated with an HATi alone or a combination of an HATi with metformin, as compared to metformin alone. Moreover, metformin, an HATi, and a combination of an HATi with metformin also modified the mRNA expression of SIRT-1, PCAF, CBP, and p300. However, metformin did not change the expression of the studied genes in 1.2B4 cells. The results of the Western blot analysis showed that metformin diminished the protein expression of PCAF in both the 1.2B4 and PANC-1 cells. Hence, it appears possible that PCAF may be involved in the metformin-mediated apoptosis of PC cells. MDPI 2023-01-12 /pmc/articles/PMC9863441/ /pubmed/36678613 http://dx.doi.org/10.3390/ph16010115 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Szymczak-Pajor, Izabela
Drzewoski, Józef
Świderska, Ewa
Strycharz, Justyna
Gabryanczyk, Anna
Kasznicki, Jacek
Bogdańska, Marta
Śliwińska, Agnieszka
Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels)
title Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels)
title_full Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels)
title_fullStr Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels)
title_full_unstemmed Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels)
title_short Metformin Induces Apoptosis in Human Pancreatic Cancer (PC) Cells Accompanied by Changes in the Levels of Histone Acetyltransferases (Particularly, p300/CBP-Associated Factor (PCAF) Protein Levels)
title_sort metformin induces apoptosis in human pancreatic cancer (pc) cells accompanied by changes in the levels of histone acetyltransferases (particularly, p300/cbp-associated factor (pcaf) protein levels)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863441/
https://www.ncbi.nlm.nih.gov/pubmed/36678613
http://dx.doi.org/10.3390/ph16010115
work_keys_str_mv AT szymczakpajorizabela metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels
AT drzewoskijozef metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels
AT swiderskaewa metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels
AT strycharzjustyna metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels
AT gabryanczykanna metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels
AT kasznickijacek metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels
AT bogdanskamarta metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels
AT sliwinskaagnieszka metformininducesapoptosisinhumanpancreaticcancerpccellsaccompaniedbychangesinthelevelsofhistoneacetyltransferasesparticularlyp300cbpassociatedfactorpcafproteinlevels